The current financial and economic climate has made it difficult for mid-stage companies to grow and succeed – currently the norm at the moment is to experience contraction.
However, one company which is bucking that trend is Innova Biosciences, which continues to experience great success with its range of Lightning-Link™ bioconjugation kits. The end products of the kits – conjugates, are used in diagnostic tests in hospitals and research labs around the world and in consumer items such as pregnancy test kits.
Global sales, from USA through to Europe and Asia Pacific, continue to grow strongly, which has been achieved through the recent development of an international distribution network and an effective PR campaign. For instance, Innova Biosciences produced a video to demonstrate the benefits of the technology to the scientific community.
As a result of increased demand for its product range, Innova Biosciences recently created several new positions within the organisation. This success comes just after the company was awarded, as part of a consortium, an EU grant to develop a platform for biomarker discovery.
Commenting on the continued success of Innova Biosciences, Nick Gee (CEO):
‘In the current economic climate it is refreshing to see the business undergoing organic growth, which has been generated through robust strategic planning and the hard work of the Innova Biosciences’ team.’
About the company: Innova Biosciences is a growing, dynamic business, based in Cambridge, UK. At the core of Innova’s business is the Lightning-Link™, an innovative technology that simplifies production of bioconjugates for use in R&D applications, drug discovery and diagnostics. The expanding Lightning-Link™ portfolio currently consists of over 40 products and is sold to research laboratories in over 30 countries around the world.
